How Will Avecho’s $4.8M Sandoz Deal Shape Its Clinical and Commercial Future?

• Revenue up 79.4% to $560,069, driven by licensing and product sales
• Loss after tax increased 23% to $2.68 million due to higher R&D and admin expenses
• Received $4.8 million upfront licensing fee from Sandoz for Australian CBD insomnia product
• Phase III clinical trial recruitment accelerated, targeting interim results in early 2026